临床T1-2、N0口咽鳞状细胞癌患者的治疗模式与结局:原发治疗方式与人乳头瘤病毒状态的相互作用
该回顾性队列研究利用美国国家癌症数据库(2010-2016年)分析1451例临床T1-2、N0口咽鳞状细胞癌患者,比较根治性放疗与机器人辅助原发手术的应用模式及结局。HPV阳性肿瘤占58.30%,30.25%的患者接受原发手术。在HPV阳性肿瘤中,手术联合辅助放疗组较单纯放疗组生存改善(HR 0.27;95%CI 0.12, 0.62;p=0.002)。
要点
- 1451例临床T1-2、N0口咽鳞状细胞癌患者中,HPV阳性肿瘤占58.30%,30.25%接受原发手术。
- 舌根部位和临床T1肿瘤分别与更高的手术可能性相关(p<0.05)。
- HPV阳性肿瘤中,手术联合辅助放疗组较单纯放疗组生存改善(HR 0.27;95%CI 0.12, 0.62;p=0.002)。
核心结论
- 本研究为早期口咽鳞状细胞癌的治疗模式与结局提供了流行病学视角。
研究设计与样本
- 回顾性队列分析,使用美国国家癌症数据库2010-2016年数据,纳入临床T1-2、N0口咽鳞状细胞癌患者1451例。
主要发现
- HPV阳性肿瘤占58.30%,接受原发手术者占30.25%。
- 舌根部位和临床T1肿瘤分别与更高的手术可能性相关(p<0.05)。
- 手术患者病理显示:淋巴血管侵犯占15.95%,淋巴结外侵犯占16.67%,T分期上调占19.36%,N分期上调占30.00%。
- HPV阳性肿瘤中,手术联合辅助放疗组较单纯放疗组生存改善(HR 0.27;95%CI 0.12, 0.62;p=0.002)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To examine the pattern of utilization and outcomes of definitive radiotherapy (RT) versus primary robotic-assisted surgery in patients with early-stage oropharyngeal squamous cell carcinoma (OPSCC). METHODS: A retrospective cohort analysis of patients with clinically T1-2, N0 OPSCC was performed using the National Cancer Database, 2010-2016. RESULTS: A total of 1451 patients were included. Prevalence of human papillomavirus (HPV)-positive tumors was 58.30%. Primary surgery was performed in 30.25% of the sample. Tongue base and clinically T1 tumors were each associated with a higher likelihood of undergoing surgery (p < 0.05). Histopathology of patients who underwent surgery demonstrated a prevalence of 15.95% with lymphovascular invasion, 16.67% with extranodal extension, 19.36% were T updated, and 30.00% were N upstaged. Improved survival was observed in the surgery + adjuvant RT group compared to RT alone for HPV-positive tumors (HR: 0.27; 95%CI: 0.12, 0.62; p = 0.002). CONCLUSION: This study provides epidemiological perspective regarding management pattern and outcomes of patients with early-stage OPSCC.
引用
- Al-Qurayshi Z, Zhu VL, Bayon R, et al. Presentation and outcomes of patients with clinically T1-2, N0 oropharynx squamous cell carcinoma: The interplay of primary treatment modality and human papillomavirus status. Head Neck. 2022. PMID: 36205359. doi:10.1002/hed.27211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。